We reviewed data from the Vitamin Intervention for Stroke Prevention (VISP) trial. 16 The VISP trial was a multicenter, doubleblind, randomized, controlled trial performed at centers across the United States, Canada, and Scotland, which enrolled 3680 patients Background and Purpose-Expert consensus guidelines recommend low-density lipoprotein cholesterol as the primary serum lipid target for recurrent stroke risk reduction. However, mounting evidence suggests that other lipid parameters might be additional therapeutic targets or at least also predict cardiovascular risk. Little is known about the effects of nontraditional lipid variables on recurrent stroke risk. Methods-We analyzed the Vitamin Intervention for Stroke Prevention study database comprising 3680 recent (<120 days) noncardioembolic stroke patients followed up for 2 years. Independent associations of baseline serum lipid variables with recurrent ischemic stroke (primary outcome) and the composite end point of ischemic stroke/coronary heart disease/ vascular death (secondary outcomes) were assessed. Results-Of all variables evaluated, only triglycerides/high-density lipoprotein cholesterol (HDL-C) ratio was consistently and independently related to both outcomes: compared with the lowest quintile, the highest triglycerides/HDL-C ratio quintile was associated with stroke (adjusted hazard ratio, 1.56; 95% confidence interval, 1.05−2.32) and stroke/coronary heart disease/vascular death (1.39; 1.05−1.83), including adjustment for lipid modifier use. Compared with the lowest quintile, the highest total cholesterol/HDL-C ratio quintile was associated with stroke/coronary heart disease/vascular death (1.45; 1.03−2.03). Low-density lipoprotein cholesterol/HDL-C ratio, non-HDL-C, elevated triglycerides alone, and low HDL-C alone were not independently linked to either outcome. Conclusions-Of various nontraditional lipid variables, elevated baseline triglycerides/HDL-C and total cholesterol/ HDL-C ratios predict future vascular risk after a stroke, but only elevated triglycerides/HDL-C ratio is related to risk of recurrent stroke. Future studies should assess the role of triglycerides/HDL-C as a potential therapeutic target for global vascular risk reduction after stroke. (Stroke. 2014;45:3269-3274.)
A reduction in serum low-density lipoprotein cholesterol (LDL-C) concentrations can substantially decrease stroke incidence, 1 but even with aggressive LDL lowering, there remains a substantial residual risk of recurrent vascular events after stroke. [2] [3] [4] Indeed, emerging evidence suggests that nontraditional serum lipid variables may be better predictors of vascular risk than LDL-C. [5] [6] [7] For instance, triglycerides/high-density lipoprotein cholesterol (HDL-C) ratio is a marker of deleterious small-dense LDL particles, 7 and patients with elevated triglycerides and low HDL-C plus high LDL-C are more likely than those with isolated LDL-C elevation to have increased risk for coronary heart disease (CHD) events, 8, 9 and triglycerides/HDL-C ratio is a powerful independent predictor of all-cause mortality and cardiovascular events. 6 Furthermore, total cholesterol (TC)/HDL-C ratio, 9, 10 LDL-C/HDL-C ratio, 11 and non-HDL-C 5, 9 have all been independently linked with greater CHD risk.
The few published studies that have explored the link between nontraditional serum lipid variables and stroke risk largely focused on incident stroke in people who were generally free of stroke or CHD at baseline. [12] [13] [14] [15] Little is known about the effects nontraditional serum lipid variables have on recurrent vascular risk after a recent stroke. The objective of this study was to assess the relationships of 4 baseline nontraditional serum lipid measures (triglycerides/HDL-C, TC/ HDL-C, LDL-C/HDL-C ratios, and non-HDL-C) to recurrent vascular risk after a recent noncardioembolic stroke.
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to determine whether high doses of multivitamin (folic acid, pyridoxine, and cobalamin) given to lower total homocysteine levels would reduce the risk of recurrent stroke and major vascular events in patients with a nondisabling noncardioembolic ischemic stroke. 16 Details of methods and main results of the trial have been reported previously. 16 Briefly, the VISP population included patients who experienced a nondisabling ischemic stroke within the preceding 120 days. Demographic, clinical, and laboratory data were collected at baseline, with subsequent clinical and laboratory information obtained at follow-up visits of 6, 12, and 24 months. Serum lipid samples were designed to be obtained after an overnight 12-hour fast, which was suitable for this study because TC, LDL-C, and HDL-C are reduced ≤3 to 5 hours after the last meal, whereas triglycerides levels were increased ≤6 hours after the last meal. 17 Based on the routine serum lipid profiles obtained, we computed 4 nontraditional lipid variables as follows: triglycerides/HDL-C, TC/ HDL-C, LDL-C/HDL-C ratios, and non-HDL-C (TC-HDL-C), all of which have at least once been reported as a predictor of cardiovascular risk in the literature. 5, 6, [8] [9] [10] [11] If an LDL-C value was missing, it was calculated using the Friedewald formula (LDL-C=TC-HDL-C−triglycerides/5). 18 Otherwise, subjects with other missing serum lipid values or those with serum levels of triglycerides ≥400 mg/ dL were excluded because LDL-C could not be calculated using the Friedewald equation. 18 For each eligible patient, further medication information, including lipid modifying therapy (ie, statin, ezetimibe, fenofibrate, niacin, or omega-3 fatty acids), antihypertensive, and antithrombotic medication was obtained at the last follow-up visit. Last follow-up visit was defined as the last documented study encounter that preceded either a vascular outcome event or end of the trial. We assessed a last follow-up visit approach (versus baseline visit) because (1) the number and type of prescriptions for secondary stroke prevention can vary during the postdischarge follow-up setting 19 and (2) our prelim evaluation of the VISP data indicated that several hundred patients had their baseline prescriptions modified to include more therapeutic drug classes (ie, lipid modifier) at the time of their 2nd or 3rd (and further) follow-up visits. All participants provided written informed consent before enrollment.
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Outcomes
The primary outcome for this analysis was ischemic stroke. Secondary outcome was a composite of stroke, CHD, including myocardial infarction, coronary revascularization, cardiac resuscitation, and fatal CHD, or vascular death as major vascular events.
Statistical Analysis
Data were summarized as mean±standard deviation or number of subjects (percentage), as appropriate. Comparisons across the groups were examined using the χ 2 test for categorical variables and one-way analysis of variance, followed by the Dunnett test for multiple comparisons, for continuous variables. For the purpose of this analysis, subjects were analyzed according to the 4 serum lipid variable groups (triglycerides/HDL-C, TC/HDL-C, LDL/HDL-C ratios, and non-HDL-C), and each of the 4 groups was stratified into quintiles according to the distribution of lipid variables. The resulting ranges of quintile were ≤1.93 (first quintile), 1.94 to 2.86 (second quintile), 2.87 to 4.05 (third quintile), 4.06 to 6.21 (fourth quintile), and ≥6.22 (fifth quintile) for triglycerides/HDL-C ratio; ≤3.50 (first quintile), 3.51 to 4.20 (second quintile), 4.21 to 4.98 (third quintile), 4.99 to 5.97 (fourth quintile), and ≥5.98 (fifth quintile) for TC/ HDL-C ratio; ≤1.92 (first quintile), 1.93 to 2.48 (second quintile), 2.49 to 3.04 (third quintile), 3.05 to 3.80 (fourth quintile), and ≥3.81 (fifth quintile) for LDL-C/HDL-C ratio; and ≤120 (first quintile), 121 to 143 (second quintile), 144 to 164 (third quintile), 165 to 190 (fourth quintile), and ≥191 (fifth quintile) for non-HDL-C. The lowest quintile was the referent group for purposes of comparison. Cox proportional hazard regression analyses were performed to estimate the risk of outcome events. Patients not having these events were censored at the date of nonvascular death, last follow-up examination, or last contact. All the analyses were performed first adjusting for age and sex, then for baseline covariates that were associated with the higher quintile (P<0.10) in each of 4 lipid variables groups. Results are given by hazard ratio and its 95% confidence interval. A linear trend of adjusted hazard ratios across increasing quintile of each lipid variable was examined using a likelihood ratio test. All analyses were conducted using IBM SPSS Version 22.0 (IBM SPSS Inc, Chicago, IL), and a probability value of <0.05 was considered statistically significant.
Results
Subjects Characteristics by Each Lipid Variable Quintile
Baseline demographic and clinical characteristics according to triglycerides/HDL-C ratio quintile and TC/HDL-C ratio quintile are provided in Table I in the online-only Data Supplement. Of 3680 subjects enrolled in VISP, triglycerides/ HDL-C ratio measurements were available in 3385 (92.0%) subjects and TC/HDL-C ratio in 3440 (93.5%) subjects. In triglycerides/HDL-C ratio group with complete data, mean age was 66.3±10.8 years, 37.8% were women and 79.5% were white, and all of them were similar in the TC/HDL-C ratio group (66.2±10.8 years; 37.8% and 79.7%, respectively). During an average of 20 months of follow-up, a total of 272 (8.0%) incident strokes and 564 (16.7%) stroke/CHD/vascular death were recorded in the triglycerides/HDL-C ratio group and 279 (8.1%) incident strokes and 572 (16.6%) stroke/ CHD/vascular death in the TC/HDL-C ratio group. For the triglycerides/HDL-C ratio group, subjects in the higher quintile had higher body mass index and LDL-C, greater frequencies of men, hypertension, diabetes mellitus, history of prior stroke, history of any cardiac disease (myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery), smoking, antihypertensive use, and lipid modifier use, but were younger and less likely to be nonwhite. For TC/HDL-C ratio group, subjects in the higher quintile had higher body mass index, LDL-C and National Institutes of Health Stroke Scale (NIHSS) score, greater frequencies of men, diabetes mellitus, smoking and lipid modifier use, whereas age was younger. Table II in the online-only Data Supplement shows baseline demographic and clinical characteristics according to LDL-C/ HDL-C ratio quintile and non-HDL-C quintile. LDL-C/ HDL-C ratio measurements were available in 3383 (91.9%) subjects and non-HDL-C in 3440 (93.5%) subjects. In LDL-C/HDL-C ratio group, mean age was 66.3±10.8 years, 37.8% were women and 79.5% were white, and all were comparable to the non-HDL-C group (66.2±10.8 years, 37.8% and 79.7%, respectively). A total of 272 (8.0%) incident strokes and 562 (16.6%) stroke/CHD/vascular death were recorded in the LDL-C/HDL-C ratio group and 279 (8.1%) incident strokes and 572 (16.6%) stroke/CHD/vascular death in the non-HDL group. For LDL-C/HDL-C ratio group, subjects in the highest quintile were more likely to have higher levels of body mass index, diastolic blood pressure, triglycerides, and NIHSS score, have higher frequencies of men, smoking, and lipid modifier use, whereas age was younger and days from stroke to randomization was more likely to be shorter. For non-HDL-C group, subjects in the highest quintile were more likely to have higher levels of body mass index and systolic/ 
Effects of Each Lipid Variable on Risk of Vascular Events
For triglycerides/HDL-C ratio, after adjusting for multiple confounders, compared with the lowest quintile at baseline, the highest quintile was associated with increased risk of stroke (1.56, 1.05−2.32; P trend =0.002) and stroke/CHD/vascular death (1.39, 1.05−1.83; P trend <0.001) ( Figure 1 ). We investigated independent effect of triglycerides and HDL-C, respectively, on vascular outcomes, but neither the highest triglycerides quintile nor the lowest HDL-C quintile itself was associated with primary or secondary outcome after multivariable Cox analyses (data not shown). For TC/HDL-C ratio, the highest quintile was associated with increased risk of stroke/ CHD/vascular death (1.45, 1.03−2.03; P trend =0.002), when referenced to the first quintile ( Figure 2 ) but not of stroke (1.35, 0.83−2.20; data not shown). For LDL-C/HDL-C ratio and non-HDL-C, none of them showed significant association with primary or secondary outcome event (data not shown). The adjusted hazard ratios of covariates included in the adjusted risk models of vascular outcomes by triglycerides/HDL-C or TC/HDL-C ratio are given in Table III in the online-only Data Supplement. In the triglycerides/HDL-C ratio group, age, diabetes mellitus, prior stroke history, and lipid modifier use were significant predictors of both the primary and secondary outcomes. In the TC/HDL-C ratio group, age, men, diabetes mellitus, smoking, and stroke severity (NIHSS) were significantly associated with stroke/CHD/vascular death.
Discussion
We observed that in this analysis of prospectively collected data on >3300 patients with a recent ischemic stroke, despite higher rate of lipid modifier use, elevated triglycerides/HDL-C ratio was significantly associated with higher risk of recurrent stroke and major vascular events during 2-year follow-up period. Although another nontraditional lipid variable, TC/ HDL-C ratio was also independently linked with major vascular events, only triglycerides/HDL-C ratio was related to recurrent stroke risk. Interestingly, we also noted that history of a stroke before the VISP-qualifying stroke occurred more frequently among those with higher triglycerides/HDL-C quintile (a finding not seen with the other lipid variable), perhaps indirectly supporting the notion that patients with elevated triglycerides/HDL-C ratio are, especially, stroke-prone. Overall, these results suggest that elevated triglycerides/HDL-C ratio may be of prognostic value for identifying high-risk subjects predisposed to stroke among recent noncardioembolic stroke populations already receiving secondary prevention. A population-based prospective cohort study found no relation of stroke risk with higher levels of triglycerides/HDL-C ratio.
14 This discrepant result may explain that all the participants in that study were healthy people free of stroke or CHD at baseline. However, atherogenic dyslipidemia as defined by HDL-C ≤40 mg/dL and triglycerides ≥150 mg/dL has been associated with greater risk of recurrent stroke 90 days after a transient ischemic attack, 4 and with higher residual cardiovascular risk among ischemic stroke and transient ischemic attack patients receiving statin therapy. 20 High triglycerides constitutes an independent risk factor for first-ever ischemic stroke in patients with CHD 21 and in general population. 22 Higher HDL-C is protective on ischemic stroke risk, 15 and lower HDL-C is associated with CHD and stroke risk. 23, 24 In this study, triglycerides or HDL-C by itself was not significantly associated with primary or secondary outcome after a recent stroke in multivariable Cox analyses. Few studies have specifically examined the independent predictive value of either higher triglycerides or lower HDL-C alone on recurrent vascular risk after an ischemic stroke, but an analysis of symptomatic intracranial atherosclerotic disease patients also did not find a link between either higher triglycerides or lower HDL-C and recurrent vascular risk. 25 The highest TC/HDL-C quintile showed significantly increased risk of the composite vascular end point but not of stroke, which is a roughly similar pattern to findings from Zhang et al study. 15 We did not observe LDL-C/HDL-C ratio to be associated with vascular outcomes, which may be because of the more heterogeneous nature of ischemic stroke, compared with CHD and our recurrent vascular event outcomes. Apolipoprotein (apo) B and apoAI is the major apolipoprotein in LDL-C and HDL-C, respectively. ApoB/apoAI ratio predicts incident stroke among patients with preexisting CHD 26 and has been recognized as a better predictor of cardiovascular risk than traditional cholesterol measures. 27 Association between non-HDL-C and ischemic stroke remains uncertain. Our result is consistent with the studies 28, 29 that non-HDL-C is not associated with stroke risk in either men or women. However, a recent large prospective Chinese cohort study showed positive association of non-HDL-C with stroke risk. 30 Because a cross-sectional study showed that large-artery atherosclerotic stroke was associated with elevated levels of non-HDL-C, 31 prospective studies are warranted to determine if non-HDL-C has predictive value for atherosclerotic stroke (versus lacunar infarction).
HDL-raising fibrate (gemfibrozil) was associated with a relative reduction by 25% and 24% in the rate of stroke and major vascular events, respectively, 32 but the vascular-protective benefits of HDL-boosting has been questioned because another HDL-raising agent (niacin) did not reduce risk of major vascular events in 2 distinct trials. 33, 34 These latter results may cast doubt on the clinical relevance of therapeutic interventions for modulating higher triglycerides/HDL-C or TC/HDL-C ratio. It is also conceivable that the residual risk noted among stroke patients can be ascribed to delayed initiation of lipid-lowering therapies during the period of highest risk 35 or an inability to achieve/maintain an intensive LDL-C level (<70 or <100 mg/ dL) over the longer term. 36 Of note, proprotein convertase subtilisin-kexin type 9 is a newly established prime modulator of plasma LDL-C and triglycerides. 37 Fenofibrate significantly decreased levels of serum proprotein convertase subtilisinkexin type 9 and triglycerides in statin-treated patients with type 2 diabetes mellitus. 38 In a recent phase III trial, proprotein convertase subtilisin-kexin type 9 inhibitor (evolocumab 420 mg) revealed promising results that showed significantly reduced levels of LDL-C (57% reduction versus statin) and triglycerides, while elevating HDL-C for 12-month follow-up period. 39 For now, our results simply suggest that triglycerides/HDL-C ratio could be an "indicator of residual vascular risk" and not necessarily a therapeutic/preventive target until clear evidence of such clinical benefit is proven.
This study has several limitations. First, it is a post hoc analysis of a completed randomized trial, and so VISP population may not be representative of the overall stroke patient population, thereby limiting generalizability. Second, only baseline and no follow-up serum lipid data were available. Third, although we adjusted for these factors and numerous other covariates in our multivariable models, there is a possibility of unmeasured confounding, particularly metabolic syndrome, which is associated with low HDL-C and elevated triglycerides levels 40 or higher apoB/apoAI ratio. 41 We could not adjust for metabolic syndrome or apoB/apoAI ratio
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because of nonavailability of serum glucose and apolipoprotein levels in the VISP database. Finally, the study comprised mostly white subjects (80%), and thus its results cannot be readily extrapolated to the patients of other races and ethnicities. However, this study was strengthened by the rigorous procedures of the prospective VISP trial design and inclusion of noncardioembolic stroke subjects with large sample size. 16 In conclusion, among 4 atherogenic nontraditional serum lipid variables, higher triglycerides/HDL-C ratio after a recent ischemic stroke seems to be the better risk prognosticator of recurrent vascular events, including stroke. Consequently, it is possible that the addition of fenofibrate to statin therapy may, especially, benefit patients with diabetes mellitus with higher triglycerides and lower HDL-C, 42 and since stroke patients with higher triglycerides/HDL-C (and TC/HDL-C) ratio were more likely to have diabetes mellitus in the VISP population, the potential role of combination lipid modifier therapy for ischemic stroke patients with residual atherogenic dyslipidemia needs to be further elucidated.
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November 2014 1 § Defined as history of myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery. ¶ Includes angiotensin-converting enzyme inhibitors, angiotensin II receptor blocker, peripheral sympatholytic, central sympatholytic, β-blockers, α-blockers, α-and β-blockers, diltiazem or verapamil, other calcium channel blocker, loop active diuretic, thiazide diuretic, and potassium-sparing diuretic. BP indicates blood pressure; NIHSS, qualifying stroke National Institutes of Health Stroke Scale; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol.
SUPPLEMENTAL MATERIAL Supplemental
NIHSS score* 1 (0−2) 1 (0−2) 1 (0−3) 1 (0−2) 1 (0−3) 0.288 b 1 (0−2) 1 (0−2) 1 (0−2) 1 (0−3) a 1 (0−3) 0
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Supplemental Table II Baseline Demographic and Clinical Characteristics of Subjects by LDL-C/HDL-C Ratio Quintile and non-HDL-C Quintile, Respectively
Quintile of LDL-C/HDL-C Ratio P Holter recording detected AF in only 3% of patients, whereas a 1-month automated recording detected AF in 16% of patients. This study indicates that with better control of coronary risk factors, stroke subtypes have changed markedly in the past 10 years, with a doubling of the proportion of patients with cardioembolic stroke/TIA. Our findings should motivate physicians who see patients at risk of recurrent stroke to investigate more intensively for a cardioembolic cause, because diagnosis of cardioembolic stroke should lead to a change in preventive therapy.
Quintile of non-HDL-C
P 1 (n=686) 2 (n=668) 3 (n=677) 4 (n=677) 5 (n=675) 1 (n=709) 2 (n=682) 3 (n=695) 4 (n=675) 5(n=679NIHSS score* 1 (0−2) 1 (0−2) b 1 (0−2) 1 (0−3) a 1 (0−3) 0.005 1 (0−2) 1 (0−2) 1 (0−3) 1 (0−2) 1 (0−3) 0
Conclusions
With more intensive medical therapy, a significant decrease in atherosclerotic risk factors was observed, with a significant decrease in strokes/TIAs caused by large artery atherosclerosis or small vessel disease. As a result, there was a significantly increasing trend in cardioembolic stroke/TIA among patients presenting with minor or moderate stroke/TIA between 2002 and 2012. Our findings suggest that more intensive investigation is appropriate to detect cardiac sources of embolism. This is important because it means that more patients will need anticoagulation for the prevention of recurrent stroke. period. Although another nontraditional lipid variable, TC/ HDL-C ratio was also independently linked with major vascular events, only triglycerides/HDL-C ratio was related to recurrent stroke risk. Interestingly, we also noted that history of a stroke before the VISP-qualifying stroke occurred more frequently among those with higher triglycerides/HDL-C quintile (a finding not seen with the other lipid variable), perhaps indirectly supporting the notion that patients with elevated triglycerides/HDL-C ratio are, especially, stroke-prone. Overall, these results suggest that elevated triglycerides/HDL-C ratio may be of prognostic value for identifying high-risk subjects predisposed to stroke among recent noncardioembolic stroke populations already receiving secondary prevention. A population-based prospective cohort study found no relation of stroke risk with higher levels of triglycerides/HDL-C ratio.
14 This discrepant result may explain that all the participants in that study were healthy people free of stroke or CHD at baseline. However, atherogenic dyslipidemia as defined by HDL-C ≤40 mg/dL and triglycerides ≥150 mg/dL has been associated with greater risk of recurrent stroke 90 days after a transient ischemic attack, 4 and with higher residual cardiovascular risk among ischemic stroke and transient ischemic attack patients receiving statin therapy. 20 High triglycerides constitutes an independent risk factor for first-ever ischemic stroke in patients with CHD 21 and in general population. 22 Higher HDL-C is protective on ischemic stroke risk, 15 and lower HDL-C is associated with CHD and stroke risk. 23, 24 In this study, triglycerides or HDL-C by itself was not significantly associated with primary or secondary outcome after a recent stroke in multivariable Cox analyses. Few studies have specifically examined the independent predictive value of either higher triglycerides or lower HDL-C alone on recurrent vascular risk after an ischemic stroke, but an analysis of symptomatic intracranial atherosclerotic disease patients also did not find a link between either higher triglycerides or lower HDL-C and recurrent vascular risk. 25 The highest TC/HDL-C quintile showed significantly increased risk of the composite vascular end point but not We observed that in this analysis of prospectively collected data on >3300 patients with a recent ischemic stroke, despite higher rate of lipid modifier use, elevated triglycerides/HDL-C ratio was significantly associated with higher risk of recurrent stroke and major vascular events during 2-year follow-up Adjusted hazard ratios (AHRs) for vascular events by increasing strata of triglycerides/HDL-C ratio. Ranges for triglycerides/HDL-C quintile (Q) were 1st, ≤1.93; 2nd, 1.94 to 2.86; 3rd, 2.87 to 4.05; 4th, 4.06−6.21; and 5th, ≥6.22. CHD indicates coronary heart disease; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol. *Adjusted for age, sex, ethnicity (white vs nonwhite), body mass index, hypertension, diabetes mellitus, LDL-C, smoking, prior stroke history (before index stroke), any cardiac disease (history of myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery), antihypertensive use, and lipid modifier use.
